Cadrenal Therapeutics, Inc. (CVKD)

Market Cap	6.83M
Revenue (ttm)	n/a
Net Income (ttm)	-8.36M
Shares Out	16.01M
EPS (ttm)	-0.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	108,416
Open	0.422
Previous Close	0.407
Day's Range	0.396 - 0.440
52-Week Range	0.360 - 3.140
Beta	n/a
Analysts	Strong Buy
Price Target	3.50 (+720.63%)
Earnings Date	May 8, 2024

About CVKD

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Po...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 20, 2023
• Employees: 4
• Stock Exchange: NASDAQ
• Ticker Symbol: CVKD

Analyst Forecast

According to 2 analysts, the average rating for CVKD stock is "Strong Buy." The 12-month stock price forecast is $3.5, which is an increase of 720.63% from the latest price.

Price Target

$3.5

(720.63% upside)

Analyst Consensus: Strong Buy